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Abstract Reconstituted influenza virus envelopes (virosomes)
containing the viral hemagglutinin (HA) have attracted attention
as delivery vesicles for cytosolic drug delivery as they possess
membrane fusion activity. Here, we show that influenza
virosomes can be targeted towards ovarian carcinoma cells
(OVCAR-3) with preservation of fusion activity. This was
achieved by incorporating poly(ethylene glycol) (PEG)-deriva-
tized lipids into the virosome membrane. This PEG layer serves
as shield to prevent interaction of HA with ubiquitous sialic acid
residues and as spatial anchor for antibody attachment. Coupling
of FabP fragments of mAb 323/A3 (anti-epithelial glycoprotein-2)
to the distal ends of PEG lipids resulted in specific binding of
virosomes to OVCAR-3 cells. These antibody-redirected viro-
somes fused with membranes of OVCAR-3 cells in a pH-
dependent fashion. ß 2001 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
The cytosol of cells is an important but relatively inacces-
sible compartment for many therapeutic macromolecules. Due
to unfavorable physicochemical characteristics, in particular
large size, these molecules often show restricted ability to
pass through cell membranes. There is a strong need for a
carrier that can deliver these often membrane-impermeable
macromolecules into the cytosol of target cells. Although lipo-
somes have been widely used for the delivery of therapeutic
compounds to target cells, liposome-mediated delivery of
membrane-impermeable macromolecular agents into the cyto-
sol remains ine⁄cient. This is mainly due to the poor endo-
somal/lysosomal escape of these agents after cellular uptake in
liposome-encapsulated form. In fact, often the main destina-
tion of liposome-encapsulated macromolecules is intralysoso-
mal degradation [1^3]. One approach to enhance cytosolic
delivery through escape from the endosomes is the use of
reconstituted envelopes (virosomes) of the human in£uenza
virus A [4^7].
The human in£uenza virus is an enveloped virus which
enters its host cell by receptor-mediated endocytosis [8,9].
The acidic environment within the endosomes triggers fusion
of the viral envelope with the endosomal membrane resulting
in release of viral nucleic acids into the cytosol of the host cell.
Both receptor binding and low pH-induced membrane fusion
are mediated by the viral integral membrane protein hemag-
glutinin (HA), which is present as trimers in the viral envelope
[10,11]. Each HA monomer consists of two subunits: HA1,
which contains the sialic acid binding pocket, and HA2, which
mediates membrane fusion. At low pH a conformational
change occurs within HA resulting in the exposure of the
hydrophobic N-termini of the HA2 subunits at the distal
ends of the HA trimers. These hydrophobic sequences interact
with target membranes thereby inducing membrane fusion.
Reconstituted in£uenza virus envelopes (virosomes) contain-
ing HA have been developed that retain fusogenic activity and
can be utilized as carriers for the delivery of normally mem-
brane-impermeable substances into the cytosol of cells [5,12^
14]. However, in£uenza virosomes have a tropism for sialic
acid-bearing cells. Since sialic acid residues are present on the
cell surface of many di¡erent cell types, targeting of in£uenza
virosomes to speci¢c cell types for the purpose of drug deliv-
ery is a challenge. In order to obtain cell speci¢city, in£uenza
virosomes have to be redirected. Redirection involves two
steps. First, binding of in£uenza virosomes to its natural re-
ceptor (i.e. sialic acid residues) has to be prevented, and sec-
ond, speci¢c homing devices (e.g. antibodies) have to be in-
troduced. Despite these modi¢cations fusogenic activity must
be preserved. Although binding and fusion are integrated in
one protein, studies have shown that HA-mediated fusion can
occur without HA-mediated binding to sialic acid cell surface
receptors as long as the HA protein is present in its native
form [15,16].
This study shows for the ¢rst time that in£uenza virosomes
can be redirected to speci¢c cell types without loss of fuso-
genic activity. For redirection we used the steric shielding
capacity of poly(ethylene glycol) (PEG) that, when exposed
on the virosome membranes, may e¡ectively prevent HA from
binding to sialic acid residues on target cell membranes. De-
pendent on the PEG chain length and the PEG density on the
surface, HA-mediated binding to sialic acid residues was fully
inhibited. By conjugating antibody FabP fragments of mAb
323/A3 (directed against epithelial glycoprotein-2) to the distal
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ends of surface-exposed PEG molecules, antigen-speci¢c bind-
ing of in£uenza virosomes to ovarian carcinoma cells with full
retention of fusogenic activity was obtained.
2. Materials and methods
2.1. Chemicals and reagents
Octa(ethylene glycol)-mono(n-dodecyl) ether (C12E8) was from Cal-
biochem (Darmstadt, Germany). The hydrophobic resin Bio-Beads
SM-2 were from Bio-Rad (Hercules, CA, USA). Before use, Bio-
Beads kept in methanol were extensively washed with HEPES-bu¡-
ered salt solution (HBS; 5 mM HEPES, 150 mM NaCl, pH 7.4).
PyrPC (1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phospho-
choline) was from Molecular Probes (Eugene, OR, USA). Neuramin-
idase from Clostridium perfringens was obtained from Sigma-Aldrich
Co. (St. Louis, MO, USA). PEG-5000-DSPE (1,2-distearoyl-glycero-
3-phosphoethanolamine-N-[poly(ethylene glycol)5000]), PEG-2000-
DSPE (1,2-distearoyl-glycero-3-phosphoethanolamine-N-[poly(ethyl-
ene glycol)2000]) and N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihex-
adecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt
(NBD-PE) were from Avanti Polar Lipids (Alabaster, AL, USA).
Maleimide-PEG-2000-DSPE was obtained from Shearwater polymers
(Huntsville, AL, USA). Iso-octylphenoxypolyethoxyethanol (Triton
X-100) was from BDH (Poole, UK). All other chemicals were from
the highest grade available.
2.2. Cells and viruses
The X47 recombinant strain of in£uenza virus, carrying the HA of
in£uenza A/Victoria/3/75, was grown and puri¢ed as described else-
where [17]. Human erythrocytes were isolated from whole blood of a
healthy volunteer as described elsewhere [18]. The human ovarian
cancer cell lines NIH:OVCAR-3 [19] and A2780 [20] were maintained
in DMEM (Gibco BRL, Grand Island, NY, USA) containing 3.7 g/l
sodium bicarbonate, 4.5 g/l L-glucose and supplemented with 10%
heat inactivated fetal calf serum, L-glutamine (4.5 g/l), penicillin
(100 IU/ml) and streptomycin (100 Wg/ml) and amphothericin B
(0.25 Wg/ml).
2.3. Virosome preparation
Reconstitution of in£uenza virus envelopes was carried out accord-
ing to [4], with some minor modi¢cations. Brie£y, an amount of virus
corresponding to 1.5 Wmol of phospholipid was pelleted by ultracen-
trifugation for 1 h at 100 000Ug using a ¢xed angle rotor. Pelleted
virus was resuspended in 0.5 ml of 30 mM C12E8 in HBS and incu-
bated for 30 min at room temperature. To incorporate pyrPC and
PEG-DSPE conjugates into the virosome membrane, solubilized viral
components were added to either pyrPC or a mixture of pyrPC and
PEG-DSPE after removal of the nucleoprotein complex by centrifu-
gation at 100 000Ug for 30 min. The amount of pyrPC relative to the
total amount of phospholipid was 10%, the amount of PEG-DSPE
varied from 0 to 20%. To be able to conjugate FabP molecules to the
virosomes, the sulfhydryl-reactive maleimide-PEG2000-DSPE was in-
corporated at a 2% lipid density. The mixture was added to 45 mg
(dry weight) of Bio-Beads prewashed in HBS and incubated for 2 h on
a shaking device (1400 rpm) at room temperature while protected
from light. Subsequently, two batches of 25 mg of fresh Bio-Beads
were added to the mixture within a time interval of 30 min while
shaking was continued. For targeting purposes, FabP fragments of
mAb 323/A3 were irreversibly conjugated to the distal ends of mal-
eimide-derivatized PEG-DSPE incorporated in the virosome mem-
brane as previously described for liposomes [21,22]. The formed viro-
somes were layered onto a discontinuous sucrose gradient (10^40^50^
60%) and centrifuged at 100 000Ug for 90 min at 4‡C. The virosomes
sedimented onto the 40% sucrose band were collected and dialyzed
overnight against 1 l of HBS at 4‡C.
2.4. Preparation of reconstituted membrane vesicles from erythrocytes
and ovarian carcinoma cells
Erythrocyte membrane vesicles (erythrocyte ghosts) were prepared
according to the method of Steck et al. [23]. Membrane vesicles com-
posed of the reconstituted membranes of OVCAR-3 cells were pre-
pared essentially as described before [24]. A total amount of 1U107
OVCAR-3 cells were collected from culture £asks and washed twice
with 10 ml of PBS by consecutive centrifugation (200Ug, 5 min) and
resuspension steps. Pelleted cells were resuspended in 5 ml of hypo-
tonic bu¡er (10 mM Tris^HCl; 1 mM MgCl2 ; 1 mM KCl; 0.5 mM
phenylmethylsulfonyl£uoride (PMSF), pH 7.3) and subjected to four
freeze/thaw cycles with liquid nitrogen and lukewarm water, respec-
tively. The resulting suspension was vigorously shaken for 5 min and
centrifuged at 1000Ug for 5 min to remove cell debris. Supernatant
was collected, and remaining pellets were washed twice with isotonic
bu¡er (10 mM Tris^HCl; 140 mM NaCl; 0.5 mM PMSF, pH 7.3).
Pooled supernatants were centrifuged at 100 000Ug and pellet was
solubilized into 3 ml 150 mM OG in HBS by incubating at 37‡C
for 30 min. After removal of insoluble cell debris by centrifugation
(700Ug ; 5 min), the clear solution was applied to a Slide-A-Lyzer
dialysis cassette (Pierce, Rockford, IL, USA) with a molecular weight
cut o¡ of 10 000 Da and dialyzed against 1 l of HBS overnight at 4‡C.
The formed membrane vesicles were collected and analyzed for size
distribution, phospholipid and protein contents.
2.5. Membrane fusion assay
Membrane fusion experiments were carried out essentially as de-
scribed before [15]. In short, virosomes at a ¢nal concentration of 2.5
WM phospholipid and donor membranes (either erythrocyte ghosts or
OVCAR-3 membrane vesicles at a ¢nal concentration of 50 WM or
200WM phospholipid, respectively) were added to a thermostatted and
stirred cuvette that contained HBS. After 2 min, the pH of the me-
dium in the cuvette was lowered to 5.1 by adding 1/20 volume of
fusion bu¡er (0.1 M 2-[N-morpholino]ethanesulfonic acid (MES);
0.1 M acetic acid pH 4.1). Fusion was continuously monitored at
37‡C by measuring the decrease in pyrPC excimer £uorescence with
a LS50B £uorescence spectrophotometer (Perkin-Elmer, Norwalk,
CT, USA) set at an excitation wavelength of 345 nm and an emission
wavelength of 480 nm. The decrease of £uorescence was expressed
relative to the di¡erence in the initial £uorescence and the excimer
£uorescence at in¢nite dilution, which was obtained by adding 70 Wl
of 10% (v/v) Triton X-100 in HBS.
2.6. Hemagglutination (HA) assay
The hemagglutination assay was carried out essentially as described
[25]. In short, 100 Wl of virosomes at a starting concentration of 68
WM phospholipid were applied to the ¢rst well of each row in a V-
shaped 96-well plate and a 2-fold serial dilution was made to obtain a
concentration of virosomes corresponding to 8.3 nM of phospholipid
in the last well of each row. Human erythrocytes were isolated from
whole blood as described by Yoneda et al. [18]. A 0.5% (volume of
pelleted erythrocytes) suspension of freshly isolated erythrocytes in
HBS was prepared, and 100 Wl of this suspension was applied to
each well. Erythrocytes were allowed to sediment overnight after
which the occurrence of agglutination was screened by visual inspec-
tion.
2.7. Cell binding of virosomes, PEG virosomes and
PEG immunovirosomes
Cell binding of virosomes, PEG virosomes and antibody-targeted
PEG virosomes (all £uorescently labeled with NBD-PE) was assessed
by £ow cytometry. Virosomes (10 WM of phospholipid) were added to
2U105 OVCAR-3 or A2780 cells and incubated for 120 min at 4‡C in
the dark. Hereafter, cells were washed twice with wash bu¡er (1%
BSA in HBS), and cells were resuspended in 500 Wl wash bu¡er before
analysis with a FACScan £ow cytometer (Becton Dickinson, Moun-
tain View, CA, USA).
3. Results
3.1. E¡ect of surface-exposed PEG on sialic acid binding
The in£uence of the presence of PEG molecules exposed on
the surface of virosomes on the capacity to agglutinate human
red blood cells was determined with a hemagglutination test
[25]. This test is based on HA-mediated binding to sialic acid-
containing receptors present on red blood cells. In£uenza vi-
rosomes bearing HA bind to these receptors and cause clump-
ing or agglutination of red blood cells in suspension. The
presence of PEG molecules exposed to the surface of viro-
somes may inhibit HA-mediated sialic acid binding. Indeed,
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binding of in£uenza virosomes to red blood cells negatively
correlated with the molecular weight and density of surface-
exposed PEG (Table 1). For PEG-2000-DSPE, 20 mol% was
needed to fully block agglutination of red blood cells ; the
same result could be achieved with 8 mol% PEG-5000-DSPE.
3.2. E¡ect of surface-exposed PEG on membrane fusion
As PEG molecules anchored to the surface of virosomes
inhibit HA-mediated sialic acid binding, we investigated the
e¡ect of surface-exposed PEG on the rate and extent of fusion
with erythrocyte membranes induced by low pH exposure.
Inclusion of PEG reduced the degree of lipid mixing between
erythrocyte ghosts and PEG virosomes (Fig. 1). At PEG den-
sities that fully block hemagglutination (8 mol% PEG-5000-
DSPE and 20 mol% PEG-2000-DSPE, see Table 1), the rate
of lipid mixing was drastically reduced compared to virosomes
without membrane-coupled PEG.
3.3. Coupling of antibody fragments to PEGylated virosomes
FabP fragments of mAb 323/A3, directed against the epithe-
lial glycoprotein-2 (EGP-2), were conjugated to the distal ends
of lipid-anchored PEG chains present in the virosome mem-
brane in order to achieve antibody-mediated binding to OV-
CAR-3 cells. In£uenza virosomes without PEG bound to both
A2780 (EGP-2 negative) and OVCAR-3 (EGP-2 positive) cells
(Fig. 2), most likely by HA-mediated binding to sialic acid
residues present on the tumor cells. Incorporation of 20 mol%
PEG-2000-DSPE (hemagglutination inhibitory concentration)
inhibited the binding to both types of tumor cells. 323/A3-
PEG virosomes only bound to OVCAR-3 cells, expressing
EGP-2 (to which the conjugated antibody is directed), and
not to A2780 cells, which lack this cell surface receptor.
Thus, by conjugating FabP fragments to the distal ends of
PEG chains present on the virosome surface, in£uenza viro-
somes could be speci¢cally redirected to OVCAR-3 cells.
3.4. Fusogenic activity of redirected in£uenza virosomes
To determine whether binding of 323/A3-PEG virosomes
via antigen/antibody interaction results in fusion comparable
to virosomes that bind to target membranes via the natural
HA/sialic acid interaction, the degree of lipid mixing induced
by virosomes, PEG virosomes or 323/A3-PEG virosomes with
reconstituted membranes of OVCAR-3 cells (referred to as
OVCAR-3 membrane vesicles) was measured. We were unable
to measure lipid mixing between virosomes and intact cells
with the pyrPC assay, due to a very high scattering signal
when intact cells were used. Therefore, membrane vesicles
were prepared from crude membrane extracts of OVCAR-3
cells according to the method of Bergers et al. [24]. These
reconstituted cell membranes bear all the membrane proteins
and lipids of the native cell membranes, among which the
EGP-2 cell surface antigen and sialylated proteins and lipids.
Because of their relatively small size (100^200 nm), their scat-
tering signal is much lower than that of whole cells. The
results show that PEG virosomes containing 20 mol% of
PEG-2000-DSPE were not able to induce lipid mixing with
OVCAR-3 membrane vesicles upon lowering the pH of the
incubation medium to 5.1. As expected, plain virosomes in-
duced lipid mixing with OVCAR-3 membrane vesicles. The
extent of lipid mixing was lower than that with erythrocyte
ghosts as acceptor membranes. This may be related to di¡er-
ences in the density of sialylated receptors expressed on the
surface of the membrane vesicles. It is well known that eryth-
Table 1
E¡ect of PEG exposed on the surface of virosomes on the capacity of virosomes to agglutinate human red blood cells (hemagglutination) as a
measure for the degree of sialic acid residue binding
Virosome preparation Dilution 2 4 8 16 32 64 128 256 512 1024 2048 4096
25 WM 1 2 3 4 5 6 7 8 9 10 11 12
0% PEG A + + + + + + + + + + + +
2% PEG-5000 B + + + + + + + þ 3 3 3 3
5% PEG-5000 C þ þ 3 3 3 3 3 3 3 3 3 3
8% PEG-5000 D 3 3 3 3 3 3 3 3 3 3 3 3
10% PEG-2000 E + + + + + þ 3 3 3 3 3 3
13.5% PEG-2000 F þ þ 3 3 3 3 3 3 3 3 3 3
20mol% PEG-2000 G 3 3 3 3 3 3 3 3 3 3 3 3
No virosomes H 3 3 3 3 3 3 3 3 3 3 3 3
A serial dilution of the di¡erent virosome preparations was made and added to a 0.5% suspension of human red blood cells. After incubation
for 3 h at room temperature to allow sedimentation of non-agglutinated red blood cells, the occurrence of agglutination was visually scored. +
indicate wells positive for agglutination; 3 indicate wells negative for agglutination and þ indicate wells where agglutination is observed to-
gether with sedimentation of red blood cells.
Fig. 1. E¡ect of surface-exposed PEG on fusion of in£uenza viro-
somes with erythrocyte ghosts. Erythrocyte ghosts (50 WM phospho-
lipid) were added to pyrPC-labeled virosomes (2.5 WM phospholip-
id). At the time point indicated with the arrow, the medium was
acidi¢ed to pH 5.1. Pyrene excimer £uorescence was continuously
monitored at 37‡C, whilst stirring the cuvette contents. The decrease
of £uorescence was expressed relative to the di¡erence in the initial
£uorescence and the excimer £uorescence at in¢nite dilution (i.e.
after vesicle solubilization with detergent). Curve a: unmodi¢ed vi-
rosomes; curve b: virosomes prepared with 8 mol% of PEG-5000-
DSPE; curve c: virosomes prepared with 20 mol% PEG-2000-
DSPE.
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rocyte membranes are a rich source of sialic acid-bearing gly-
colipids and glycoproteins. When 323/A3-PEG virosomes
were added to OVCAR-3 membrane vesicles and the pH of
the medium was lowered to 5.1, a very low degree of lipid
mixing was observed (results not shown). After pre-binding of
the 323/A3-PEG virosomes to the surface of OVCAR-3 mem-
brane vesicles for 1 h at room temperature, the extent of lipid
mixing was as high as with unmodi¢ed virosomes (Fig. 3A).
Treatment of OVCAR-3 membrane vesicles with neuramini-
dase to remove the sialic acid residues resulted in a drastically
decreased level of lipid mixing induced by virosomes but only
slightly altered the degree of lipid mixing observed for 323/A3-
PEG virosomes, indicating that in the latter case target cell
binding is mainly mediated by antibody/antigen interaction
and not by binding of HA to sialic acid residues (Fig. 3B).
4. Discussion
The results presented here show that in£uenza virosomes
can be redirected to ovarian carcinoma cells with full reten-
tion of fusogenic activity. In the past, unsuccessful attempts
have been made to target virosomes prepared from the recon-
stituted envelopes of Sendai virus and in£uenza virus to spe-
ci¢c cell surface receptors [26^29]. The lack of success of tar-
geting can be ascribed to the dominance of the natural
binding tropism of the virosomes. Studies with in£uenza virus
have demonstrated that removal or modi¢cation of the HA1
domain, responsible for binding to the ubiquitous sialic acid
residues, results in an impaired fusogenic activity mediated by
the HA2 domain [30,31]. In addition, introduction of new,
speci¢c targeting elements by chemical conjugation of proteins
to HA (personal observation) or by creating chimeric HA-
scFv proteins at a genetic level [26] also result in loss of
fusogenic activity of the HA protein. In this study we have
chosen for a di¡erent approach to redirect in£uenza viro-
somes without the need to modify HA. Inspired by the well-
described use of PEG to shield surface-exposed proteins on
colloidal systems, as recently demonstrated for in£uenza viro-
somes by Chams et al. [32], we have anchored PEG to the
surface of in£uenza virosomes by incorporating PEG lipids
into the viral envelope for two reasons: (1) to sterically shield
HA, thereby preventing it from interacting with its natural
ligand sialic acid, and (2) to use the surface-grafted PEG layer
as a spacer to conjugate speci¢c homing devices to the distal
ends of the PEG chains in order to obtain speci¢c binding to
target cells without destruction of the HA protein. The
present results con¢rm that high concentrations of surface-
grafted PEG (20 mol% PEG-2000-DSPE or 8 mol% PEG-
5000-DSPE) on the virosomes fully block the binding of vi-
rosomes to sialic acid-bearing receptors on human erythro-
cytes. Whether this inhibition of binding is caused by steric
shielding of the sialic acid binding pocket of HA by incorpo-
rated PEG lipids is not completely certain. X-ray crystallog-
raphy has demonstrated that HA molecules protrude 13.5 nm
from the viral membrane surface [33]. The e¡ective thickness
of the PEG coat has been reported to be approximately 6.5^7
nm at a surface coverage of 9 mol% PEG1900 and 15 nm for
PEG5000 at 7 mol% surface coverage [34]. Considering the
dimensions of the PEG layer and the HA protein (13.5 nm)
one would expect that only PEG-5000 would be able to steri-
Fig. 2. Virosome binding to OVCAR-3 cells (expressing high levels of the target receptor EGP-2) and A2780 cells (no EGP-2 expression). Viro-
somes, PEG-2000 virosomes (prepared with 20 mol% PEG-2000-DSPE) and 323/A3 FabP-PEG-2000 virosomes (prepared with 20% PEG-2000-
DSPE), all labeled with 0.1% NBD-PE, were incubated with either OVCAR-3 cells or A2780 cells (1U106 cells/ml) for 1 h at 4‡C at a concen-
tration of 10 WM phospholipid. Unbound virosomes were removed by two centrifugal wash steps before cells were analyzed by £ow cytometry.
Histograms in black show the £uorescence intensity of 3000 cells incubated in bu¡er. White overlays show the £uorescence intensity of 3000
cells after incubation with the indicated virosome preparation.
FEBS 25501 26-11-01
E. Mastrobattista et al./FEBS Letters 509 (2001) 71^7674
cally shield the sialic acid binding pocket of HA. However, we
observed that PEG-2000-DSPE incorporated in the virosome
membrane at a density of 20 mol% also blocks the binding of
in£uenza virosomes to erythrocytes. High densities of surface-
grafted PEG cause the PEG chains to stretch out (i.e. brush
formation) [35]. So, it may well be possible that the PEG
chains have a fully-stretched conformation in our PEG-2000
virosomes. With a fully-stretched conformation, which has a
theoretical dimension of 15.8 nm (45 units of ethylene glycol
of 3.5 Aî each), the HA protein would be shielded. However, it
cannot be excluded that other mechanisms than steric shield-
ing also play a role in the mechanism of sialic acid binding
hindrance by the PEG layer [36].
It should be noted that the amount of PEG lipids that can
be incorporated in bilayers is limited due to the tendency of
PEG lipids to form mixed micelles above a certain concentra-
tion [37]. Indeed, we observed that the recovery of viral phos-
pholipids present in the virosome particles after removal of
micelles and protein aggregates by density gradient centrifu-
gation was low (recovery between 30 and 40%) at the highest
PEG lipid concentration used (20 mol% PEG-2000) compared
to virosome preparations without PEG lipids (recovery be-
tween 70 and 80%). This indicates that solubilization of com-
ponents from the viral envelope (lipids, spike proteins) into
mixed micelles has occurred in the preparation with the high-
est concentration of PEG lipids. Nevertheless, functional vi-
rosome particles containing PEG lipids could be isolated.
Previous studies have shown that in£uenza virus HA-medi-
ated fusion is independent of binding to sialic acid [15]. The
binding step can be replaced by any other molecular interac-
tion such as biotin/streptavidin interactions, which indicates
that fusion is independent of any speci¢c behavioral property
of the underlying (cell surface) protein or lipid to which the
sialic acid is linked. Presumably, the only functions of the HA
binding to sialic acid residues are to initiate receptor-mediated
endocytosis of the virosome particles and to hold the viro-
some in close proximity of the endosomal membrane while
the membrane fusion takes place. This study demonstrates
that binding of in£uenza virosomes via antibody^antigen in-
teraction results in speci¢c binding and subsequent membrane
fusion. The antibody FabP fragments are displayed on the
outer edge of the PEG layer whereas the sialic acid binding
pocket of HA is shielded by the same PEG layer. Therefore,
the initial binding event of the virosomes to the target cell
surface will be accomplished by the exposed antibody frag-
ments. In view of the dimensions of the HA molecule (see
above), it cannot be excluded that the initial binding of anti-
body to cell surface antigen, which brings the virosome par-
ticles in close proximity of the glycocalyx of the cell mem-
brane favors the chance of HA to interact with sialic acid
residues as a second binding mode.
The choice of targeting ligand for redirecting in£uenza vi-
rosomes is critically important. Not only should it allow spe-
ci¢c binding of virosomes to target cell surface receptors, but
binding should also lead to receptor-mediated endocytosis, as
the virosome will only become fusogenic at the low pH envi-
ronment within endosomes. Indeed, it has been reported that
the antibody used here as targeting ligand is internalized after
binding to EGP-2 [38,39].
Besides the advantage of grafted PEG lipids to shield the
binding function of HA, it may also prevent or inhibit un-
wanted immune recognition of the antigenic viral HA proteins
after systemic administration of PEG virosomes. Studies with
PEGylated adenoviruses have demonstrated that surface PEG
molecules can inhibit the antibody response against viral pro-
teins [40,41]. In vivo pharmacokinetic studies on repeated in-
jections of PEGylated in£uenza virosomes should be per-
formed to address this issue.
In conclusion, this study demonstrates that in£uenza viro-
somes can be redirected towards ovarian carcinoma cells by
incorporating PEG lipids into the virosome membrane with
conjugated antibodies at the distal ends of PEG chains. Stud-
ies to address whether these antibody-redirected in£uenza vi-
rosomes can be utilized for enhancement of the cytosolic de-
livery of otherwise cell-impermeable substances are currently
underway in our laboratory.
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ing the manuscript.
Fig. 3. Fusion of in£uenza virosomes with OVCAR-3 membrane
vesicles (A) or OVCAR-3 membrane vesicles treated with neuramin-
idase to remove sialic acid residues (B). OVCAR-3 membrane
vesicles (200 WM phospholipid) were added to pyrPC-labeled viro-
somes (2.5 WM phospholipid). At the time point indicated with an
arrow, the medium was acidi¢ed to pH 5.1, and fusion was moni-
tored as previously described (see legend to Fig. 1). Results were
obtained with virosomes (a); virosomes prepared with 20% PEG-
2000-DSPE (b); and antibody-targeted virosomes also prepared with
20% PEG-2000-DSPE (c).
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